195 related articles for article (PubMed ID: 21751166)
1. The influence of non-radioactive iodine (127I) on the outcome of radioiodine (131I) therapy in patients with Graves' disease and toxic nodular goitre.
Rogowski F; Abdelrazek S; Szumowski P; Zonenberg A; Parfienczyk A; Sawicka A
Nucl Med Rev Cent East Eur; 2011; 14(1):9-15. PubMed ID: 21751166
[TBL] [Abstract][Full Text] [Related]
2. Antithyroid drugs as a factor influencing the outcome of radioiodine therapy in Graves' disease and toxic nodular goitre?
Körber C; Schneider P; Körber-Hafner N; Hänscheid H; Reiners C
Eur J Nucl Med; 2001 Sep; 28(9):1360-4. PubMed ID: 11585295
[TBL] [Abstract][Full Text] [Related]
3. Iodine-131 treatment of hyperthyroidism: significance of effective half-life measurements.
Berg GE; Michanek AM; Holmberg EC; Fink M
J Nucl Med; 1996 Feb; 37(2):228-32. PubMed ID: 8667049
[TBL] [Abstract][Full Text] [Related]
4. Radioiodine therapy compared in patients with toxic nodular or Graves' hyperthyroidism.
Franklyn JA; Daykin J; Holder R; Sheppard MC
QJM; 1995 Mar; 88(3):175-80. PubMed ID: 7767667
[TBL] [Abstract][Full Text] [Related]
5. Iodine-131 given for therapeutic purposes modulates differently interferon-gamma-inducible alpha-chemokine CXCL10 serum levels in patients with active Graves' disease or toxic nodular goiter.
Antonelli A; Rotondi M; Fallahi P; Grosso M; Boni G; Ferrari SM; Romagnani P; Serio M; Mariani G; Ferrannini E
J Clin Endocrinol Metab; 2007 Apr; 92(4):1485-90. PubMed ID: 17244787
[TBL] [Abstract][Full Text] [Related]
6. Long-term follow-up study of radioiodine treatment of hyperthyroidism.
Metso S; Jaatinen P; Huhtala H; Luukkaala T; Oksala H; Salmi J
Clin Endocrinol (Oxf); 2004 Nov; 61(5):641-8. PubMed ID: 15521969
[TBL] [Abstract][Full Text] [Related]
7. [Treatment of hyperthyroidism caused by Graves' disease or toxic multinodular goitre by radioiodine: over 80% cure retrospectively after one calculated dose].
Bakker SC; Zanin DE; Zweers EJ
Ned Tijdschr Geneeskd; 2002 Sep; 146(39):1837-41. PubMed ID: 12382370
[TBL] [Abstract][Full Text] [Related]
8. Administration of additional inactive iodide during radioiodine therapy for Graves' disease: who might benefit?
Dietlein M; Moka D; Reinholz U; Schmidt M; Schomäcker K; Schicha H; Wellner U
Nuklearmedizin; 2007; 46(3):77-84. PubMed ID: 17549318
[TBL] [Abstract][Full Text] [Related]
9. Dosimetry of radioiodine therapy in patients with nodular goiter after pretreatment with a single, low dose of recombinant human thyroid-stimulating hormone.
Nieuwlaat WA; Hermus AR; Ross HA; Buijs WC; Edelbroek MA; Bus JW; Corstens FH; Huysmans DA
J Nucl Med; 2004 Apr; 45(4):626-33. PubMed ID: 15073259
[TBL] [Abstract][Full Text] [Related]
10. The occurrence of hypothyroidism following radioactive iodine treatment of toxic nodular goiter is related to the TSH level.
Adamali HI; Gibney J; O'Shea D; Casey M; McKenna TJ
Ir J Med Sci; 2007 Sep; 176(3):199-203. PubMed ID: 17632747
[TBL] [Abstract][Full Text] [Related]
11. Different strategies to overcome the effect of carbimazole on high- and low-dose radioiodine therapy: results from continuous dose-effect models.
Walter MA; Schindler C; Christ-Crain M; Müller-Brand J; Müller B
Eur J Clin Invest; 2009 Jan; 39(1):51-7. PubMed ID: 19087129
[TBL] [Abstract][Full Text] [Related]
12. Radioiodine treatment of hyperthyroidism: prognostic factors affecting outcome.
Erem C; Kandemir N; Hacihasanoglu A; Ersöz HO; Ukinc K; Kocak M
Endocrine; 2004 Oct; 25(1):55-60. PubMed ID: 15545707
[TBL] [Abstract][Full Text] [Related]
13. Appearance of thyroid stimulating antibody and Graves' disease after radioiodine therapy for toxic nodular goitre.
Chiovato L; Santini F; Vitti P; Bendinelli G; Pinchera A
Clin Endocrinol (Oxf); 1994 Jun; 40(6):803-6. PubMed ID: 8033373
[TBL] [Abstract][Full Text] [Related]
14. [Radioiodine treatment of hyperthyroidism using a simplified dosimetric approach. Clinical results].
Giovanella L; De Palma D; Ceriani L; Vanoli P; Garancini S; Tordiglione M; Tarolo GL
Radiol Med; 2000 Dec; 100(6):480-3. PubMed ID: 11307510
[TBL] [Abstract][Full Text] [Related]
15. Outcome of 131I therapy in hyperthyroidism using a 550MBq fixed dose regimen.
Lewis A; Atkinson B; Bell P; Courtney H; McCance D; Mullan K; Hunter S
Ulster Med J; 2013 May; 82(2):85-8. PubMed ID: 24082285
[TBL] [Abstract][Full Text] [Related]
16. [Determination of factors affecting the therapeutic outcome of radioiodine therapy in patients with Graves' disease].
Sabri O; Schulz G; Zimny M; Schreckenberger M; Zimny D; Wagenknecht G; Kaiser HJ; Dohmen BM; Bares R; Büll U
Nuklearmedizin; 1998 May; 37(3):83-9. PubMed ID: 9604227
[TBL] [Abstract][Full Text] [Related]
17. [Effect of iodine application during radioiodine therapy in patients with impending therapy failure].
Urbannek V; Schmidt M; Moka D; Hillger HW; Voth E; Wellner U; Schicha H
Nuklearmedizin; 2000; 39(4):108-12. PubMed ID: 10919161
[TBL] [Abstract][Full Text] [Related]
18. Radioiodine treatment of hyperthyroidism in patients with low thyroid uptake.
Ruchała M; Sowiński J; Dolata M; Junik R; Gembicki M; Skiba A
Nucl Med Rev Cent East Eur; 2005; 8(1):28-32. PubMed ID: 15977144
[TBL] [Abstract][Full Text] [Related]
19. Radiometabolic treatment of hyperthyroidism with a calculated dose of 131-iodine: results of one-year follow-up.
Regalbuto C; Marturano I; Condorelli A; Latina A; Pezzino V
J Endocrinol Invest; 2009 Feb; 32(2):134-8. PubMed ID: 19411811
[TBL] [Abstract][Full Text] [Related]
20. Radioactive iodine therapy in Graves' hyperthyroidism: a prospective study from a tertiary referral centre in north India.
Sankar R; Sekhri T; Sripathy G; Walia RP; Jain SK
J Assoc Physicians India; 2005 Jul; 53():603-6. PubMed ID: 16190128
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
